<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101139</url>
  </required_header>
  <id_info>
    <org_study_id>SIMAR</org_study_id>
    <nct_id>NCT01101139</nct_id>
  </id_info>
  <brief_title>Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery</brief_title>
  <official_title>Small Dose of Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery (TOF 0.9)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate, whether Sugammadex improves muscle function after
      standard neuromuscular recovery (TOF 0.9) from relaxation with rocuronium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Muscle relaxants are an integral part of today's anesthesia. They improve intubating
      conditions and reduce doses of other substances needed for general anesthesia. For ensuring
      patient safety, neuromuscular function is monitored during general anesthesia. The latter one
      is only terminated, when neuromuscular monitoring shows an objective normal value. Despite
      this accurate surveillance, a lot of patients complain about subjectively uncomfortable
      muscle weakness in the recovery room. A possible explanation for this ostensive contradiction
      can be the variable &quot;margin of safety&quot; of neuromuscluar transmission in different muscle
      groups. Waud et al describe this phenomenon, as the fact, that neuromuscular transmission is
      only clinically detectable, when a certain number of post-synaptic receptors is not blocked.
      The necessary fraction of free receptors differs a lot between the muscle groups (15-50%). As
      neuromuscular monitoring only measures one muscle group exemplarily, and a clinically
      non-detectable number of post-synaptic receptors can be blocked shortly after anesthesia, the
      subjective muscle weakness of patients could need treatment.

      Sugammadex can encapsulate steroid-typ muscle relaxants within 2 to 5 minutes. After applying
      a sufficiently high dose, also those receptors will be free that elude neuromuscular
      monitoring. This constellation brings up the interesting problem to quantify the possible
      effect on patients' subjective muscle weakness.

      This study is designed to investigate, if the application of sugammadex improves muscle
      function and consequently well-being of patients, that have been extubated according to
      clinical standard.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle function</measure>
    <description>Muscle function following the investigational drug</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Sugammadex 0.25 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single injection of Saline 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex (single intravenous injection 0.25 mg/kg)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: single intravenous injection Saline 0.9%</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical stauts II - III

          -  Age: 18 - 65 years

          -  Patients scheduled for general anesthesia with intubation using rocuronium

          -  Patients have given informed consent to the study

          -  Patients receiving the investigational drug within 15 minutes after neuromuscular
             recovery to a TOF 0.9

          -  Sufficient knowledge of the German language

        Exclusion Criteria:

          -  known or suspected neuromuscular disease

          -  significant hepatic or renal dysfunction

          -  known or suspected history or family history of disposition to malignant hyperthermia

          -  known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other
             drugs used for general anesthesia

          -  Use o drugs that interfere with sugammadex

          -  Patients included in another trial within the last 30 days

          -  Patients with legal guidant

          -  Patients with contradiction towards the use of Sugammadex

          -  Pregnant women

          -  Breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Blobner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anaesthesiologie Klinikum München rechts der Isar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anaesthesiologie Klinikum München rechts der Isar</name>
      <address>
        <city>Munic</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997 Oct;41(9):1095-1103.</citation>
    <PMID>9366929</PMID>
  </reference>
  <reference>
    <citation>Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008 Jul;107(1):130-7. doi: 10.1213/ane.0b013e31816d1268.</citation>
    <PMID>18635478</PMID>
  </reference>
  <reference>
    <citation>Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, Eikermann M, Khuenl-Brady KS. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008 Aug;109(2):188-97. doi: 10.1097/ALN.0b013e31817f5bc7.</citation>
    <PMID>18648227</PMID>
  </reference>
  <reference>
    <citation>Waud DR, Waud BE. In vitro measurement of margin of safety of neuromuscular transmission. Am J Physiol. 1975 Dec;229(6):1632-4.</citation>
    <PMID>1211496</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

